Dr. Kiernan is the Chairman and Chief Executive Officer of iMetabolic Biopharma Corporation (iMBP), a TechBio company that he founded in 2017.
CHANDLER, AZ, October 06, 2023 /24-7PressRelease/ -- Urban A. Kiernan, PhD, has been included in Marquis Who's Who. As in all Marquis Who's Who biographical volumes, individuals profiled are selected on the basis of current reference value. Factors such as position, noteworthy accomplishments, visibility, and prominence in a field are all taken into account during the selection process.
Dr. Kiernan is the Chairman and Chief Executive Officer of iMetabolic Biopharma Corporation (iMBP), a TechBio company that he founded in 2017. The company's focus is on the development of both proprietary therapeutics and a technology platform for the discovery and development of novel disease treatments. Dr. Kiernan holds key responsibilities surrounding both corporate operations and the development of scientific innovation. Due to the success of these efforts, he counts his progress with iMBP as his most notable career achievement thus far.
Extensive industry experience accompanies Dr. Kiernan in his leadership role which has included appointments in both large and small businesses. He began his career as a senior scientist with Intrinsic Bioprobes Inc., a start-up biotech company back in 2000. During his tenure, he was promoted to the role of Director of Biomarker Discovery in 2009 and held this position until the company was acquired by Thermo Fisher Scientific in 2011. During his time at Intrinsic Bioprobes, Inc., he honed his skills and successfully ran a number of different scientific programs that resulted in significant commercial revenue, government grant award funding and highly valuable contributions to the scientific community. After the acquisition, Dr. Kiernan integrated into Thermo Fisher Scientific and rapidly rose through the ranks to be promoted to a role in global business development within the company.
His success has also been highlighted by a number of distinguished academic and scientific merit credentials. Dr. Kiernan's profile begins with a Bachelor of Arts in Chemistry from Minnesota State University Moorhead, from which he graduated cum laude in 1996. Subsequently, he attended Arizona State University to pursue his graduate coursework in chemistry. He earned a Master of Science in 2001 and subsequently completed his PhD in Bio-analytical Chemistry in 2002. Currently, he is a member of the National Lipid Association and serves on the Arizona State University Biotechnology Advisory Board.
Now fully dedicated to iMBP, Dr. Kiernan has transitioned from diagnostics, the arena in which he began his career and dedicated over a decade of his professional life to improve, to a focus on his passion in drug discovery and development. This transition now has Dr. Kiernan innovating new therapeutic solutions to address diseases with high unmet medical need. Notably, Dr. Kiernan and iMBP's research efforts were recently recognized for their significance by the NIH as the recipient of a Phase 1 grant award earlier this year. Serving as the program's Principal Investigator (NHLBI – "Computational Development of Novel Dyslipidemia Therapeutic Candidates to Disrupt ApoC-III Conformation"), this award supports and validates both the iPlatform™, iMBP's proprietary discovery technology that was initially developed with the support of Amazon Web Services, and one of their innovative cardiovascular disease drug programs.
Dr. Kiernan has also made significant scientific contributions through the publication of dozens of peer-reviewed articles in a number of renowned scientific journals and text book chapters. Selected titles include "Precision Medicine Drugs – Pleonasm or Reality," which was published in Drug Discovery World in 2018, and in 2015, he co-authored "Insulin Detemir Does Not Cross the Human Placenta" for Diabetes Care. He also co-authored "Quantitative Measurement of Full-Length and C-Terminal Proteolyzed RBPP4 in Serum of Normal and Insulin-Resistant Humans Using a Novel Mass Spectrometry Immunoassay" for Endocrinology in 2012.
Numerous accolades and industry recognition also mark the distinct milestones of Dr. Kiernan's career thus far, including multiple NIH Phase 1 and Phase 2 funding awards, such as a NIH/NIAAA grant in 2009 for the Validation of Alcohol Exposure Biomarkers via Affinity Mass Spectrometry. He attributes his success to personal drive and an innovative thought process. This drive permeates through all aspects of Dr. Kiernan's life. This has allowed him to successfully balance the needs of family, as a husband and father of three, and his own personal growth as an avid practitioner of Brazilian Jiu Jitsu. Moreover, Dr. Kiernan acknowledges a personal tragedy, having lost his first wife to cancer in 2006, as a pivotal moment that has ultimately led him to where he is today. Looking toward the future, Dr. Kiernan aims to further advance iMBP and its innovation as he is passionate about helping others. Having personally experienced the devastation of loss, his commitment to the improvement of treating disease is unrelenting, and his success is already making positive steps forward in the areas of metabolic, cardiovascular and neurodegenerative diseases, the indications that he and the iMBP team are currently addressing.
About Marquis Who's Who®:
Since 1899, when A. N. Marquis printed the First Edition of Who's Who in America®, Marquis Who's Who® has chronicled the lives of the most accomplished individuals and innovators from every significant field of endeavor, including politics, business, medicine, law, education, art, religion and entertainment. Marquis celebrates its 125th anniversary in 2023, and Who's Who in America® remains an essential biographical source for thousands of researchers, journalists, librarians and executive search firms around the world. Marquis® publications may be visited at the official Marquis Who's Who® website at www.marquiswhoswho.com.
# # #